Enliven Therapeutics (ELVN) Preferred Stock Liabilities (2019)

Enliven Therapeutics (ELVN) posted Preferred Stock Liabilities of $77.8 million for Q4 2019, up 70.63% sequentially from $45.6 million in Q3 2019.

Enliven Therapeutics (ELVN) Preferred Stock Liabilities (2019) Analysis & Trends

Enliven Therapeutics has reported Preferred Stock Liabilities for 1 years, with the latest figure at $77.8 million in Q4 2019.

Quarterly Preferred Stock Liabilities changed N/A year-over-year to $77.8 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $77.8 million (changed N/A YoY) and the FY2019 annual result came in at $77.8 million, changed N/A from the prior year.
Preferred Stock Liabilities grew to $77.8 million in Q4 2019 per ELVN's latest filing, from $45.6 million in the prior quarter.
Over five years, Preferred Stock Liabilities peaked at $77.8 million in Q4 2019 and troughed at $1.5 million in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Enliven Therapeutics	4.31 Bn	3.41 Bn	-	-

Download Data